Biography
Dr. Claire Verschraegen is the Director of the Division of Medical Oncology at The Ohio State University James Comprehensive Cancer Center in Columbus. With more than 30 years of experience in thoracic oncology, she is a nationally recognized expert in drug development for mesothelioma, having contributed to the study of pemetrexed, gemcitabine, and other systemic agents that form the backbone of mesothelioma treatment. Dr. Verschraegen's career has been defined by her leadership in clinical trials that bring new therapeutic options to mesothelioma patients, and she directs the medical oncology program at one of the Midwest's largest NCI-designated comprehensive cancer centers.
Education & Training
- Medical Degree — University of Liège, Belgium (Medicine)
- Fellowship — MD Anderson Cancer Center (Medical Oncology)
Specialties & Procedures
Clinical Specialties
- Medical Oncology
- Thoracic Oncology
- Drug Development
As a medical oncologist, Dr. Claire Verschraegen focuses on non-surgical treatment modalities including chemotherapy, immunotherapy, targeted therapy, and clinical trials.
Board Certifications
- American Board of Internal Medicine — Medical Oncology
- American Board of Internal Medicine — Internal Medicine
Research Focus
Drug development for mesothelioma including pemetrexed and gemcitabine-based regimens, novel therapeutic agents, and clinical trial leadership for rare thoracic cancers.
Treatment Center
Dr. Claire Verschraegen practices at Ohio State James Cancer Hospital in Columbus, OH.
Legal Resources for Mesothelioma Patients
Patients diagnosed with mesothelioma after asbestos exposure may be eligible for compensation through asbestos trust funds and legal claims. Over $30 billion remains available in trust funds nationwide.
Frequently Asked Questions
What is Dr. Verschraegen's experience with mesothelioma treatment?
Dr. Verschraegen has over 30 years of experience treating mesothelioma and has been instrumental in the development of key chemotherapy agents used in mesothelioma treatment, including pemetrexed-based regimens.